## Index

absorption 42, 45, 46-7 academic context 63-71 academic detailing 67 academic medical centers 68-9, 70-1 case example 70-1 collaborative research 69 drug approval process 64 economic assessments 68 funding 411-12 future developments 69, 407, 408-13 interventional pharmacoepidemiology 67-8 logistical advances 411 methodological advances 408-9 new content areas of interest 409-11 patients' use of drugs 65-6, 67 personnel 412-13 policy analysis 67 postmarketing surveillance studies 63-4 prescribing practices 64-5, 67-8, 348 quality and outcomes of medication use 66-7 risk-benefit assessment 63 scientific developments 408-11 accessibility of data 141, 149-52, 159-60 accuracy of data 139, 158-9, 206, 210, 212-18, 353 adherence 314-23 academic context 65-6, 67 challenges in adherence measurement 315-16 clinical trials 315, 320 data analysis 316, 320-1 drug concentration assays 319 electronic drug monitors 318-20, 321-2 future developments 321-2, 410 medication diaries 318, 319 medication errors 382 metrics 321 non-pill formulations 319-20, 322 pill counts 318 refill data 317-18, 321 self-reported data 316-17, 319, 321 time-vary nature and duration of adherence intervals 320-1

administrative databases 119-21, 122, 124-5, 360, 368 adverse drug events (ADEs) 378-80, 384 adverse drug reactions (ADRs) causation 229 drug utilization studies 341 early legislation 5-6 intellectual development of pharmacoepidemiology 9-11 legal and regulatory context 3 meta-analysis 300-1, 308-10 molecular pharmacoepidemiology 242 pharmacovigilance 4-5 regulatory actions resulting from drug crises 6-8 spontaneous reporting 102-16 Type A and Type B reactions 3–4 Adverse Event Reporting System (AERS) 9, 104, 105, 108, 386, 391 adverse events (AEs) academic context 64 causation 228-38 industry context 73-4 legal context 88 meta-analysis 308-10 pharmacoeconomics 285 pharmacovigilance 5 spontaneous reporting 102-16 adverse events following immunizations (AEFIs) 350-5 Agency for Healthcare Research and Quality (AHRQ) 10-11 academic context 69, 412-14 automated databases 129, 131 comparative effectiveness research 393, 399-400 future developments 412-14 implantable medical devices 360 analyses of secular trends 21, 22, 23-4, 27 Anatomical Therapeutic Chemical (ATC) codes 158, 167, 187, 344 approved patient labeling 71, 374-5 association causal association 17, 20-21 causation 229 criteria for the causal nature of an association 20-1

*Textbook of Pharmacoepidemiology*, Second Edition. Edited by Brian L. Strom, Stephen E. Kimmel, and Sean Hennessy. © 2013 John Wiley & Sons, Ltd. Published 2013 by John Wiley & Sons, Ltd.

association (Continued) epidemiologic study designs 24-8 error types 18-20 measurement error 208-12 molecular pharmacoepidemiology 241-4, 246-54 scientific method 17, 18 strength, consistency and specificity 20-1 validity of data 208-12 automated databases 118-22, 123-77 bioethics 262 Canadian provincial databases 144-52 case examples 132-3, 143-4, 152-3, 162-3, 172-3 claims and other administrative databases 119-21, 122, 124-5.133-44 comparative effectiveness research 396-7 confounding variables 324-5, 332-3 data resources comparison 191-5 drug utilization studies 342-4, 346 future developments 122, 411 health maintenance organizations/health plans 123-33 implantable medical devices 360 medical record databases 120-1, 122, 152-63 medication errors 383-4 particular applications 121-2, 126-31, 142-3, 150-1, 161, 170-2 pharmacy-based medical record linkage systems 163-73 research questions comparison 195-201 Sentinel Initiative 385, 388, 391-2 standard data layouts 129 strengths and weaknesses 120-1, 125-6, 139-42, 150, 159-61, 169-70 teratogenicity 368 vaccine safety 354-5 validity of data 221-4 Bayesian analysis 109, 114, 234-5, 306 biases 19-20 adherence 317 bioethics 267-8 comparative effectiveness research 398-9 field studies 179-80 medication errors 382-3 meta-analysis 300-2, 303-4, 306-7 randomized controlled trials 271-2, 276 teratogenicity 366 vaccine safety 353 validity of data 206-7, 211-12 see also confounding variables bioavailability 43 bioethics 256-68 automated databases 262 case example 267 comparative effectiveness research 399 confidentiality 149 ethics review boards 261, 262-8

human subjects research 256-7, 258, 266-7 informed consent 67, 150, 259-60, 262, 267, 287 minimal risk 260-1 pharmacoepidemiologic research 257-8 potential contributions of pharmacoepidemiology 15 prescribing practices 347 privacy and confidentiality 258-9, 263-4, 266-7 biologic plausibility 20, 367 biological samples 186 birth defects see teratogenicity birth registers 166, 168-9, 172 black triangle program 106-7 blinding 272 body composition 45-6, 47 Bradford Hill criteria 89 British National Formulary 106-7 broad drug safety initiatives 77 calendar time cohorts 326 Canadian provincial databases 144-52 case example 152-3 data resources comparison 191-5 health services program 144-5, 152-3 hospitalization databases 148-9 medical services databases 147-8 particular applications 150-1 prescription drug databases 145-7, 151-3 research questions comparison 195-201 strengths and weaknesses 150 cancer registries 166, 168, 171 candidate gene approach 246-7, 250 capacity building 79, 84-5 case-cohort studies 327-8 case-control studies bioethics 262 data resources comparison 191-2, 192-5 field studies 182-3, 185 molecular pharmacoepidemiology 247-51 research questions comparison 195-6, 199 sample size 31, 33-9 study designs 22, 23-7 teratogenicity 369 validity of data 206-7, 209-11 case-crossover studies 325, 328-30 case-only studies 250-1 case report forms (CRFs) 181 case reports 22-3, 27, 105-6, 109-12, 181-2, 228-38 case series 22, 23, 27, 36-7, 110, 114 case-time-control studies 329-30 causal association 17, 20-21 causation algorithm/criterial method with verbal judgments 233 algorithms requiring scoring of individual judgments 233-4 case example 230-1 case reports 228-38

current tools and methods 233-5 future developments 236 historical perspectives 229-31 industry context 231-2 legal context 88-9 molecular pharmacoepidemiology 243-4 probabilistic methods 234-5 randomized controlled trials 270 regulatory context 232 reports to medical journals 232 spontaneous reporting 102-3, 107-11 study designs 17, 18 unstructured clinical judgment/global introspection 233 uses of causality assessment 231-2 vaccine safety 351-3 Centers for Disease Control and Prevention (CDC) 129, 354-5, 369, 414 Centers for Education and Research on Therapeutics (CERTs) 10, 85, 399, 412 Centers for Medicare and Medicaid Services (CMS) 133-8, 185, 394 chart review 383 claims databases 119-21, 123-6 133-44 case example 143-4 data resources comparison 191-5 data sources and structure 134, 137-9 demographic data 134-8 implantable medical devices 360 Medicaid/Medicare programs 133-7, 139-44 medication errors 383 particular applications 142-3 research questions comparison 195-201 strengths and weaknesses 139-42 Veterans Affairs health care 135-6, 138-44, 223-4, 344 clearance 44, 46, 49 clinical context 55, 57-8, 62 clinical decision support systems (CDSS) 378-9, 382 clinical feedback 348 clinical laboratory data 168, 170-1 clinical pharmacology absorption 42, 45, 46-7 basic principles 40-53 drug interactions 48-9 elderly patients 45-6 elimination 44, 46, 49 metabolism 43-4, 48 organ impairment 48 pediatric patients 46-7 pharmacodynamics 4, 40, 49-50 pharmacoepidemiology versus 3-5, 40-1 pharmacogenomics 50-1 pharmacokinetics 4, 40, 41-9 pharmacovigilance 4-5 pregnancy 47-8 special populations 44-9 study designs 17

Type A and Type B reactions 3-4 volume of distribution 42-3, 45-6, 48 clinical trials adherence 315, 320 comparative effectiveness research 396-9 health-related quality-of-life 294-5 meta-analysis 308-9 pharmacoeconomics 285-6, 287-8 pharmacoepidemiology versus epidemiology 5 regulatory context 81 United States context 12 see also randomized clinical trials Cochrane Collaboration 303, 399 Code of Federal Regulations (CFR) 258-61, 265 coherence with existing information 20 cohort studies case-cohort studies 327-8 confounding variables 325-8, 334 data resources comparison 191-2, 193 nested case-control studies 327 research questions comparison 195-6, 198, 199 sample size 30-3, 37-9 structures of cohorts 326-7 study designs 21, 22, 24-8 teratogenicity 367 collaborative research academic context 69 automated databases 125, 126, 129, 130 implantable medical devices 363 industry context 76-7, 78 regulatory context 79, 84-5 see also Sentinel Initiative Committee for Medicinal Products for Human Use (CHMP) 13, 72 comparability of study groups 331-2, 358 comparative effectiveness research (CER) 11, 126, 129, 393-401 automated databases 151 cost containment 401 current applications 400 definition of effectiveness 394 definitions of comparative effectiveness research 395 dissemination of evidence 399, 401 experimental studies 398-9 funding 400 future developments 400-401, 408, 410 generation of evidence 397-9, 401 historical developments 393-4 human capital development 400 implantable medical devices 356 nonexperimental studies 397-8 organizational approaches 399-400 reasonable expectations for 401 synthesis of evidence 396, 401 completeness of data 158-9, 160-2, 169-70, 206-7, 210-12, 222-4

computerized order-entry systems 68 computerized physician order entry (CPOE) 378-9, 382 concentration-effect relationships 49-50 confidence intervals 26, 30, 37, 289 confidentiality 91-2, 149, 258-9, 263-4, 266-7 confounding variables 19-20, 324-36 analysis of comparable patients 331-2 analytic approaches for improved confounding control 330-4 automated databases 121, 141 balancing patient characteristics 330 case-cohort studies 327-8 case-crossover studies 325, 328-30 case examples 335-6 case-time-control studies 329-30 cohort studies 325-8, 334 comparative effectiveness research 397 data resources comparison 191-2, 194 exposure variation 325 field studies 181 future developments 409 industry context 74-5 instrumental variable analysis 333 molecular pharmacoepidemiology 249-50, 252 nested case-control studies 327-8 new user design principle 325 propensity score analysis 330-1, 332, 335-6 proxy adjustment 332-3, 334 random aspects in treatment choice 333 randomized controlled trials 270-1, 274-5 research questions comparison 195-6, 198-9 sensitivity analysis 333-4 study designs 325-30 teratogenicity 367 unobserved patient characteristics and residual confounding 332 vaccine safety 353 validity of data 205-6 within-subject designs 325, 328-30 Congressional Budget Office 395 consistency of data 308 constructive knowledge 87-8 continuity corrections 305-6 continuous outcome variables 38 contract law 90-2, 93 control groups 32-6, 38-9 cooperativity of study population 275-6 copy number variants (CNV) 240 correlation coefficients 208 cost-effectiveness analysis 283-4, 285, 289 costs comparative effectiveness research 401 drug utilization studies 341-2 field studies 179 patients' use of drugs 66

pharmacoeconomics 281, 284, 288–9 risk-benefit assessment 54, 62 criterial method with verbal judgments 233 critical scored algorithm 231, 234 cross-sectional construct validity 293 cross-sectional studies 27 cross-sector partnerships 77 cumulative meta-analysis 309–10 Current Procedural Terminology (CPT) codes 223–4 cytochrome P450 (CYP) enzymes 43–4, 46, 48, 242, 245

data analysis adherence 316, 320-1 field studies 187-8 meta-analysis 304-6 pharmacoeconomics 287-9 randomized controlled trials 272, 277 data collection field studies 181-3, 185-6 medical record databases 155-8 meta-analysis 303-4 pharmacoeconomics 287 randomized controlled trials 272, 273-4 study designs 190 Data Extraction and Longitudinal Time Analysis (DELTA) 359 data limitations 141 data management 186-7 data mining 109, 114–15, 117, 408 data monitoring 277 data security 386, 391 data structure 134-5, 137-9, 155-8, 390 Daubert v. Merrell Dow 89-90 Dear Healthcare Professional Letters 71, 104, 115, 374 death registers 157, 166, 168-9 Declaration of Helsinki 261 defined daily dose (DDD) 342-4 demographic data automated databases 124, 128, 134-7, 140, 146-8, 156 validity of data 215, 218 Developing Evidence to Inform Decisions about Effectiveness (DEcIDE) 69, 130-1, 399 device variation 361 diagnosis data 124, 216-18, 222-3 differential misclassification 209-12 direct-to-customer advertising (DTCA) 88 disease area-specific collaborations 77 disproportionality 109, 114 dose-response relationships 21, 40, 103 drug approval process 11-13, 64 drug concentration assays 319 drug development process 281 drug-event pairs 109, 114-15, 117 drug-induced birth defects see teratogenicity drug interactions 48-9, 103, 241-4, 247-8, 250-1, 275, 381-2 drug safety initiatives 76-7

drug utilization studies 339-46 see also use patterns of a medicine duration-response relationship 21 ecological studies see analyses of secular trends economic evaluation see pharmacoeconomics effect modification 247-8, 307-8 effectiveness 66, 69, 315, 348, 356-7, 394 see also comparative effectiveness research efficacy 49, 66-7 elderly patients 45-6 electronic drug monitors (EDMs) 318-20, 321-2 electronic medical records (EMRs) 124-5, 153, 192 bioethics 262 medication errors 383-4 Sentinel Initiative 385, 390 validity of data 221, 225-6 elements to assure safe use (ETASU) 75 eligibility limitations 141 elimination 44, 46, 49 Empirical Bayes method 109 ethics see bioethics ethics review boards 261, 262-8 ethnicity 249-50, 252 European Medicines Agency (EMA) 13, 69, 84, 108 European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) 69, 77, 84, 172 Evidence-Based Practice Centers (EPCs) 399 evidence-informed practice and policy 361 examination data 124-5 experimental studies see randomized clinical trials exposure data causation 228 data resources comparison 191-5 implantable medical devices 357 research questions comparison 195-6, 199-201 validity of data 205-6, 212-16, 222 exposure databases 167, 170 exposure frequency 180 exposure variation 325 external validity see generalizability failure-to-warn liability 87-9, 93 field studies 178-89 case example 188-9 computing infrastructure 183 conduct of the study 184-7 data analysis 187-8 data collection 181-2, 185-6 data management 186-7 data resources comparison 191-5 exposure and covariate information 179 extremely rare diseases 178-9, 185, 188-9

information bias 179-80

outcome definition 178

operational principles 184

particular applications 180-8 pilot phase 183-4 protocol development 181 research questions 179, 195-201 selection bias 179 setup 182-4 strengths and weaknesses 178-80 study designs 180-2 study staff 183 study validity 179-80 subject enrollment 184-5 time, costs and logistics 179 follow-up automated databases 139 comparative effectiveness research 399 confounding variables 326-7 data resources comparison 191-2, 194, 195 randomized controlled trials 276-7 teratogenicity 368 Food and Drug Administration (FDA) automated databases 122, 129, 131 collaborative research 69, 77, 84-5 drug approval 12 early legislation 5-6 future developments 411–13 implantable medical devices 359, 361 industry context 71-2, 75-7 legal context 90 legislative actions resulting from drug crises 8-9 meta-analysis 302, 309-11 post-approval safety studies 82 potential contributions of pharmacoepidemiology 13-14 pregnancy and drug safety 47-8 regulatory actions resulting from drug crises 7-8 risk-benefit assessment 55-6 risk management 71-2, 370, 376 spontaneous reporting 103-4 vaccine safety 350-1 see also Sentinel Initiative full text records 125 funnel plots 306 gag clauses 91 Gamma Poisson Shrinker 109 gatekeeper system 153 gene discovery 246-7, 250 gene-drug interactions 241-4, 247-8, 250-1 general practitioners (GPs) 153-5 generalizability automated databases 121, 125, 159 bioethics 257-8, 266 comparative effectiveness research 395 confounding variables 332 implantable medical devices 358 medication errors 383

pharmacoeconomics 285

generalizability (Continued) randomized controlled trials 272, 278 validity of data 208-9 genetic variability 239-40, 247, 250-1 genome-wide association studies (GWAS) 246-7, 250 genotypes 240 global introspection 233 glomerular filtration rate (GFR) 44 Good Pharmacovigilance Practices (GVP) 72 GP OnLine Data (GOLD) 153-62 half-life of elimination 44 haplotypes 240 Health Improvement Network, The (THIN) 120, 153-63 Health Insurance Portability and Accountability Act (HIPAA) 184, 263-4, 267, 387, 391-2 health maintenance organizations (HMOs) 123-33, 191-201, 411 health plans 123-33, 191-201 health profiles 296 health-related quality-of-life (HRQL) 291-9 case examples 294 future developments 298 generic/specific instruments 296-8 health profiles 296 instrument attributes and potential uses 292-6, 298 instrument taxonomy and potential use 296 measures of validity 292-3 new drug investigations 292-6 properties of QoL instruments 292-6, 298 utility measurement 297 homogeneity/heterogeneity of data 305, 307, 311-12, 399 hospitalization data automated databases 148-9, 155, 158, 166, 167, 171-2 confounding variables 332 data resources comparison 191-2, 194-5 drug utilization studies 344-6 research questions comparison 195-201 validity of data 216-18, 222-3 human capital development 400 human subjects research 256-7, 258, 266-7 hypothesis generation 55, 57-8, 195, 197 hypothesis strengthening 195, 197 hypothesis testing 55, 57, 195, 197, 275 implantable medical devices 355-63 automated databases 360 benefits and harms profile in real world setting 356 case example 362 collaborative research 363 comparability of study groups 358 comparative studies 357 epidemiologic studies 355-63 evidence-informed practice and policy 361 future developments 361-3 long-term safety and effectiveness 356-7

mandated postmarketing studies 359-60 patient/population exposure assessment 357 pharmacoepidemiologic studies 362 regulatory context 361 sample size and real world performance 357-8 surveillance modes 358-9 IMS Disease-Analyzer 153-62 incidence rates automated databases 161 field studies 180 randomized controlled trials 269-70 research questions comparison 195, 198 sample size 32-4, 37 inclusion criteria 303 indication bias 271, 398-9 industry context 71-9 case example 78-9 causation 231-2 collaborative research 76-7, 78 drug regulation and product liability 90 drug safety evaluation and epidemiology 72-7 drug safety initiatives 76-7 future developments 407-8, 413 post-approval epidemiology 73-5, 78-9 preapproval epidemiology 73 risk evaluation and mitigation strategies 72, 74, 75-6 risk management and epidemiology 71-2, 78 study designs 73-5, 78-9 information bias 179-80, 382-3 informed consent 67, 150, 259-60, 262, 267, 287 Institute of Medicine (IOM) 10 bioethics 264 comparative effectiveness research 394-5, 396, 399-400 medication errors 378 risk management and epidemiology 71-2 vaccine safety 351 institutional review boards (IRBs) 159, 183, 185, 256, 261, 264 instrumental variable (IV) analysis 333, 358 integrity of data 386 intellectual property law 92, 93-4 Intensive Medicines Monitoring Programme 107 interim analyses 277 International Classification of Diseases (ICD) 119-22, 124-5, 147-8, 167, 186-7, 222-4, 386 International Conference on Harmonization (ICH) 102, 105, 107 International Network for Rational Use of Drugs (INRUD) 342, 346 international postmarketing safety databases 108-9 International Society for Pharmacoepidemiology (ISPE) 9, 257, 407 inter-reader variability 303-4 interventional pharmacoepidemiology 67-8 interviews 186-7, 317 Investigational New Drugs (INDs) 6

Kefauver-Harris Amendments 9 knowledge liability 87-8 large simple trials (LSTs) 74-5, 79, 273-8 learned intermediary rule 88, 93 legal context 86-94 adverse drug reactions 3 contract law and pharmacoepidemiology 90-2, 93 early legislation 5-6 failure-to-warn liability 87-9, 93 future developments 414 intellectual property law and pharmacoepidemiology 92, 93-4 legislative actions resulting from drug crises 8–9 pharmacoepidemiologic expertise and Daubert 89-90 potential contributions of pharmacoepidemiology 15 prescribing practices 347 risk-benefit assessment 55, 57, 62 risk management 370-1 teratogenicity 369 tort law and product liability 86-90, 93 life-cycle approach 386, 388 linkage capacity 140, 149-50 linkage disequilibrium (LD) 242, 250

literature reviews 300, 302–3 see also meta-analysis long-term safety 356–7 longitudinal construct validity 293

mandated postmarketing studies 359-60 Mantel-Haenszel procedure 304, 305-6, 329 Manufacturer and User Facility Device Experience (MAUDE) database 358, 391 marketing context 55, 56-7, 62 Markov chain Monte Carlo techniques 306 maternal linkage 168-9 measurement error 206-12, 220 adherence 318 association 211-12 indices of 206-8 misclassification of variables 209-12, 226, 318 pharmacoepidemiologic research 208-12 quantitative measurement of reliability 206, 208 quantitative measurement of validity 206-8 Medicaid program 133-7, 139-44, 222 medical journals 232, 407 medical record databases 120-1, 122, 152-63 bioethics 262 case example 162-3 data collection and structure 155-8 data resources comparison 191-5 description 155-9 particular applications 161 research questions comparison 195-201 strengths and weaknesses 159-61 medical services databases 147-8

Medicare program 135-6, 137-44, 411 medication adherence see adherence medication diaries 318, 319 medication errors 378-84 case example 381 drug utilization studies 341 future developments 384, 410 generalizability 383 information bias 382-3 patient safety concepts 379-80 safety theory 378-9 sample size 383 spontaneous reporting 105 Medication Guides 374-5 MedWatch program 8, 9, 103-4 membership status data 124 meta-analysis 300-13 analysis of rare events 305-6 bias in the abstraction of data 302 choice of statistical method 304-5 comparative effectiveness research 396-7 compatibility of studies 301 conclusions and recommendations 306 confounding variables 335-6 cumulative meta-analysis 309-10 data analysis 304-6 data collection 303-4 defining the purpose 302 differential effects among patient subgroups 308-9 effect measurement 304 future developments 311-12 implantable medical devices 358 inclusion/exclusion criteria 303 indirect and simultaneous comparison of treatments 307-8, 311-12 literature reviews 300, 302-3 procedural steps 302-7 publication bias 301-2, 306-7 regulatory context 311 signal detection 309-10 susceptibility of original studies to bias 301 variability and heterogeneity 304-5 metabolism 43-4, 48 meta-regression 305 Michaelis Menten kinetics 43 Mini-Sentinel 131, 385, 387, 392-3 minimal important difference (MID) 294-5 minimum effect size 31-3 misclassification of variables 209-12, 226, 318 missing heritability 246-7 molecular pharmacoepidemiology 239-55 case examples 243, 245, 251 confounding by population admixture 249-50 definitions and concepts 239-40 future developments 252-3 genetic variability 239-40, 247

molecular pharmacoepidemiology (Continued) gene-drug interactions and causation 243-4, 250-1 gene-drug interactions and effect modification 247-8 genome-wide versus candidate gene approaches 246-7, 250 interplay of various mechanisms 244 pharmacodynamic gene-drug interactions 242-3 pharmacogenetics and pharmacogenomics 240-1, 244-7, 253 pharmacokinetic gene-drug interactions 241-2 replication 252 research progression and application 244-5 type I/II errors 248-9, 252 multicenter evaluations 287 multi-HMO collaborations 125, 126-7, 129 Multi-item Gamma Poisson Shrinker 109 multinational economic evaluation 283 Naranjo scored algorithm 231, 234 National Drug Code (NDC) 124, 344, 357 National Institute for Health and Clinical Excellence (NICE) 11, 394 National Institutes of Health (NIH) 129, 399, 411-14 national pharmacovigilance systems 106-7 national postmarketing safety databases 108-9 negative predictive value 207, 223-4 negligence 87 nested case-control studies 327-8 New Drug Applications (NDAs) 72 new user design principle 325 nondifferential misclassification 209-12 nonrepresentativeness 140 nonresponse bias 267 number needed to treat (NNT) 296, 298 number of prescriptions 342 odds ratios 25-6, 33, 36, 39, 247-9, 304-5 once-daily therapies 321-2 one-step model 306 orphan drug applications 71 out of plan care 142 over-the-counter (OTC) medications 74, 118, 366, 369 - 70patents 92, 93-4 pathology data 166, 168, 171 Patient Package Inserts 71, 374-5 patient router files 166-7 patient variation 361 pediatric investigation plans (PIP) 71, 74 pediatric patients 46-7, 383

pediatric patients 46–7, 383 Peto method 306 pharmacodynamics 4, 40, 49–50, 242–3, 316, 318 pharmacoeconomics 280–90 academic context 68

analysis of economic and costs data 287-9 case examples 282-3 clinical trials versus common practice 285-6 cost-effectiveness analysis 283-4, 285, 289 data collection 287 drug development process 281 future developments 289-90, 409 measurement and modeling in clinical trials 287-8 multicenter evaluations 287 participation of patients 287 perspective of analysis 284 prospective studies 286-9 research trends 280-1 sample size 286-7 sensitivity analysis 284 study designs 286-9 types of costs 281, 284 uncertainty in economic assessment 289 pharmacoepidemiology, definition 3 pharmacogenetics 240-1, 244-7, 253, 408-9 pharmacogenomics 50-1, 240-1 pharmacokinetics 41-9, 241-2, 316, 318 pharmacovigilance 4-5 adverse events and adverse drug reactions 102-16 case example 116 causation 102-3, 107-11 concept of spontaneous AE/ADR reporting 103-4 future developments 115 national and international postmarketing safety databases 108-9 national pharmacovigilance systems 106-7 non-uniform temporal reporting trends 113-14 opportunity for public reporting 112 overview of pharmacovigilance reporting systems 102-3 particular applications of spontaneous reporting 114-15 report characteristics 105-6 report quality 113 reporting ratios 111-12, 114, 117 scope of postmarketing safety reporting systems 112-13 signal detection 108-9, 112, 114-15, 117 signals from developing countries 115 spontaneous reporting 8, 101-17 strengths and limitations 112-14 underreporting 113 pharmacy-based medical record linkage (PbMRLs) systems 163-73 births, deaths and maternal linkage 166, 168-9, 172 cancer registries 166, 168, 171 case example 172-3 clinical laboratory data 168, 170-1 data resources comparison 191-5 description 164-9 exposure databases 167, 170

hospitalization data 166, 167, 171-2 particular applications 170-2 pathology data 166, 168, 171 patient router files 166-7 record linkage 164-6 research questions comparison 195-201 strengths and weaknesses 169-70 pharmacy claims records 139 PHARMO record linkage system 164-73 pill counts 318 pilot studies 183-4 placebo-controlled trials 301, 307-8, 398 population-based data 159, 161, 191, 193 population size 139 population stratification 249–50, 252 positive predictive value 207, 223-4 Post-Approval Studies (PAS) Program 359 Post-authorization Safety Studies (PASS) 72 postmarketing requirements (PMR) 72 postmarketing surveillance studies academic context 63-4, 69 adherence 315 drug approval process 12-13 implantable medical devices 359-60 pharmacoepidemiology versus epidemiology 5 potential contributions of pharmacoepidemiology 14-15 risk-benefit assessment 55-8 sample size 37 Sentinel Initiative 384-5, 391 spontaneous reporting 8, 101-17 study designs 23, 27 pragmatic clinical trials 398-8 PRECEDE framework 347-8 predictive value 207, 223-4 pregnancy 47-8, 157, 382-3 see also teratogenicity prescribed daily dose (PDD) 344 prescribing practices academic context 64-5, 67-8 adherence 317-18, 321 automated databases 139, 141, 144-7, 150-3, 165.169 case example 349 conceptual framework 347-8 detecting effects on patient outcomes 347 drug utilization studies 342, 344 empirical evidence on effectiveness of interventions 348 ethical and medico-legal problems with RCTs 347 evaluating and improving 346-50 future developments 348-50 internal validity 346-7 number of prescriptions 342 patient as unit of analysis 347

refill data 317-18, 321 regression toward the mean 347 teratogenicity 366, 369-70 prescription drug databases 145-7, 151-3 Prescription Drug User Fee Act (PDUFA) 8-10, 71, 75 Prescription Event Monitoring (PEM) 9, 191-201 prevalence rates 33, 36, 161, 195, 198, 345 primary outcomes 277 prior written consent 91 privacy 258-9, 263-4, 266-7, 386, 391 probabilistic methods 234-5 procedures data 125 product liability 86-90, 93 propensity score (PS) analysis 330-1, 332, 335-6, 408.409 prospective studies 27-8, 286-9 protected health information (PHI) 391 protocol development 181 protocol-induced testing 285 provider variation 361 proxy adjustment 332-3, 334 publication bias 301-2, 306-7 quality control (QC) 186-7 Quality and Outcomes Framework (QOF) 158 quality scoring systems 303 quality-adjusted life-years (QALYs) 297 quality-of-life measurements see health-related quality-of-life quantitative strength 21 questionnaire design 214-15, 218-20 random-effects models 304-5 randomized clinical trials (RCTs) comparative effectiveness research 397-8 ethical and medico-legal problems 347 health-related quality-of-life 295-6 implantable medical devices 356, 357-8 industry context 73, 74 study designs 21, 22, 26-8 randomized controlled trials (RCTs) 269-79 adherence 315 appropriateness of large simple trials 274-5 blinding 272 case examples 270 choice of control treatment 272 data collection and analysis 272, 273-4, 277 feasibility of large simple trials 275-6 future developments 277-8 large simple trials 273-8 limitations 272-3 logistics of large simple trials 276-7 meta-analysis 309-10 overview of classic RCTs 271-2 research questions 274 sample size 271-2, 273

Rapid Cycle Analysis (RCA) 130 recall accuracy/bias 212-18, 220, 366 record linkage see pharmacy-based medical record linkage referrals data 155-6, 158 refill data 317-18, 321 regression toward the mean 347 regulatory context 79-86 adverse drug reactions 3 assessing impact of regulatory actions 83 assessing need for medicines 80 assessing use patterns of a medicine 83, 86 capacity building and collaboration 79, 84-5 causation 232 drug approval process 11-13 early legislation 5-6 future developments 408, 413-14 implantable medical devices 361 integrating data from multiple sources 79, 83-4 intellectual development of pharmacoepidemiology 9-11 meta-analysis 311 monitoring drug development programs 82 pharmacoepidemiology throughout product lifecycle 79-83, 86 planning drug development programs 80-2 policy analysis in academia 67 post-approval safety studies 80, 81-2 preapproval clinical safety data 80, 81 product liability and drug regulation 90 regulatory actions resulting from drug crises 6-8 risk-benefit assessment 54-6, 62 risk management and epidemiology 71-2 teratogenicity 369 relative risk confounding variables 333-4 legal context 89 meta-analysis 304, 305 randomized controlled trials 274-5 regulatory context 82 sample size 30-5, 37-9 study designs 25-6 vaccine safety 353 reliability of data 206, 208, 219 reporting ratios 111-12, 114, 117 representativeness 140, 191, 193 research ethics see bioethics research questions 179, 190, 195-201, 274 retrospective studies 27-8 risk acceptability 60 bioethics 260-1 characteristics of exposure 60 features of adverse outcomes 59-60 legal context 87, 89 perception of evaluators 61

randomized controlled trials 274-5 regulatory context 80, 82 safety versus 54, 58 tolerance 54, 59-61 risk assessment 372 risk-benefit assessment 54-8, 61-2 academic context 63 clinical context 55, 57-8, 62 costs 54, 62 future developments 414 implantable medical devices 355, 356 legal context 55, 57, 62 marketing context 55, 56-7, 62 randomized controlled trials 269 regulatory context 54-6, 62, 83-4 research questions comparison 195, 197-8 risk management 371-2 sample size 41 Sentinel Initiative 388 vaccine safety 351 risk communication 71, 374-5, 376 risk difference 26, 304 risk evaluation and mitigation strategies (REMS) 72, 74, 75-6, 376-7 risk evaluation studies 151 risk management 10, 370-8 academic context 408 case example 377 future developments 376 industry context 71-2, 78 iterative process and multidisciplinary nature 372 medication use system 371 proactive approach 372 regulatory context 71-2, 83 risk assessment 372 risk communication 374-5, 376 risk mitigation 373-4, 375-6 scientific approach 372 sources of risk from medical products 371-2 Risk Management Plans (RMPs) 71, 82, 376 Risk Minimization Action Plans (RiskMAPs) 71, 75 risk mitigation 373-4, 375-6 risk-sets 326-8 safety profiles 58 safety theory 378-9 sample size 30-9 automated databases 159 case-control studies 31, 33-9 case series 36-7

case-control studies 31, 33–9 case series 36–7 cohort studies 30–3, 37–9 implantable medical devices 357–8 medication errors 383 pharmacoeconomics 286–7 randomized controlled trials 271–2, 273

```
study designs 17
```

teratogenicity 364-5 vaccine safety 353 selection bias 179, 212 self-administered questionnaires 181-2 self-reported data 212-18, 221, 316-17, 319, 321 sensitivity analysis 211-12, 284, 333-4 see also completeness of data Sentinel Initiative 384-93 academic context 69 automated databases 122, 131 case example 386 data infrastructure 390 data structure 390 database linkages 390-1 developing methods for signal generation 389-90 foundational aspects of 385-7 future developments 392, 411 governance 391, 393 industry context 77 operational challenges 391 privacy and data security 386, 391 regulatory context 85 standardized data elements 390 summary measures from multiple observational data sources 389 surveillance modes 385, 388, 390 validating a safety signal 388-9 signal detection meta-analysis 309-10 pharmacovigilance 108-9, 112, 114-15, 117 vaccine safety 351, 353-4 signal evaluation 385, 388-9 signal generation 385, 389-90 signal refinement 385 signal-to-noise ratio (SNR) 293 similarity of data distribution 307-8 single nucleotide polymorphisms (SNPs) 51, 240-2, 250 small study effects 306 socioeconomic status 270-1 special populations 44-9 drug interactions 48-9 elderly patients 45-6 organ impairment 48 pediatric patients 46-7, 383 pregnancy 47-8, 157, 382-3 specificity of data 206-7, 211, 223-4 spontaneous reporting 8, 101-17 adverse events and adverse drug reactions 102-16 case example 116 case reports 105-6, 109-12 causation 102-3, 107-11 concept of spontaneous AE/ADR reporting 103-4 data resources comparison 191-5 future developments 115 medication errors 383

national pharmacovigilance systems 106-7 national/international postmarketing safety databases 108-9 non-uniform temporal reporting trends 113-14 opportunity for public reporting 112 overview of pharmacovigilance reporting systems 102-3 particular applications 114-15 report characteristics 105-6 report quality 113 reporting ratios 111-12, 114, 117 research questions comparison 195-201 scope of postmarketing safety reporting systems 112-13 signal detection 108-9, 112, 114-15, 117 signals from developing countries 115 strengths and limitations 112-14 underreporting 113 vaccine safety 352, 353-4 standard data layouts 129, 384, 390 standard error of measurement (SEM) 295 standardized incidence ratio (SIR) 327 standardized mortality ratio (SMR) 327 statistical inference 18 statistical power 31-3, 38, 273, 274-5, 369 stratified analysis 247-8, 305 study designs 17-29 advantages and disadvantages 21-2 analyses of secular trends 21, 22, 23-4, 27 automated databases 159 case-only studies 250-1 case series 22, 23, 27, 36-7, 110, 114 causal association 17, 19-21 clinical pharmacology 17 confounding variables 325-30 data resources comparison 190-5 error types 18-20 field studies 180-2 industry context 73-5, 78-9 integrating data from multiple sources 79, 83-4 large simplified trial 74-5, 78-9 pharmacoeconomics 286-9 regulatory context 79, 83-4 research questions comparison 190, 195-201 sample size 17, 30-9 scientific method 17-18 selection of study subjects 17-18 teratogenicity 367-9 see also individual study types subgroup analyses 277, 308-9 subject enrollment 184-5 subpopulation-specific collaborations 77 Summary of Product Characteristics (SmPC) 374-5 supplementary information 13, 14 surrogate markers 410 surveillance modes 358-9, 385, 388, 390

system-based interventions 382 systematic reviews 358, 396-7 Systemized Nomenclature of Medicine (SNOMED) 168 systems approach 386 teratogenicity 363-70 alleged/unknown teratogenic risk 364 automated databases 368 biologic plausibility 367 case example 365 class action teratogenesis 364 confounding variables 367 follow-up of selected exposures 368 future developments 369-70 integrated approaches 369-70 known teratogens 363-4 legal context 369 prescription and nonprescription drugs 366, 369-70 recall bias 366 regulatory actions resulting from drug crises 6-7 regulatory context 369 sample size 364-5 study designs 367-9 termination of pregnancy 367 therapeutic window 52 time sequence of events 20-1 time-to-refill approach 317-18 tort law 86-90, 93 toxicity 49, 315 transparency 109, 386 two-tailed tests 31, 32-5 Type A/B reactions 3-4 type I/II errors 30-1, 32-6, 38-9, 54, 248-9, 252

unavailable information 141 uncertainty 274, 289 unexpected effects 197–8 unique device identifiers (UDIs) 357, 361 universal consent 262 unstructured clinical judgment 233 use patterns of a medicine 65–6, 67, 83, 86, 150 *see also* adherence utility measurement 297

Vaccine Adverse Event Reporting System (VAERS) 108, 352, 353–4, 391 vaccine safety 350–5 case example 352 causation 351–3 confounding and bias 353 confounding variables 335

epidemiologic studies 354 future developments 354, 410-11 measurement accuracy 353 sample size 353 Sentinel Initiative 391 signal detection 351, 353-4 Vaccine Safety Datalink (VSD) 130, 354-5, 391 validity of data 205-27 assessment of self-reported data 221 association 211-12 automated databases 139-41, 159-60, 221-4 best practices 218-20, 224-5 case examples 213-14, 216-17, 223-4 comparator selection 221 data resources comparison 191-2, 194 field studies 179-80 future developments 225-6 measurement error 206-12, 220, 226 medical condition type 216-17 medication class 214 misclassification of variables 209-12, 226 patient population 215-16, 218 prescribing practices 346-7 quantitative measurement of reliability 206, 208 quantitative measurement of validity 206-8, 219 questionnaire design 214-15, 218-20 recall accuracy 212-18, 220 self-reported diagnosis and hospitalization data 216-18 self-reported drug data 212-16 timing of diagnosis and emotional effects on patient 217-18, 220 variability of data 304-5, 311-12, 361 Veterans Affairs (VA) health care 135-6, 138-44, 223-4, 344 VigiBase 108, 114 volume data 342 volume of distribution 42-3, 45-6, 48 voluntariness 259-60 warning and failure to warn 87-9, 93 Weber effect 113-14 weighted least squares linear regression 305 World Health Organization (WHO) drug approval 12-13 drug utilization studies 339, 342, 344, 346 pharmacovigilance and spontaneous reporting 101, 106, 108-9, 111, 114-15 vaccine safety 351 WHO Drug Dictionary 187 Wyeth v. Levine 90